Header Logo

Connection

BORIS SEPESI to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications BORIS SEPESI has written about Neoplasm Staging.
BORIS SEPESI
Connection Strength
1.334
Neoplasm Staging
  1. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
    View in: PubMed
    Score: 0.070
  2. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg. 2021 01 04; 59(1):100-108.
    View in: PubMed
    Score: 0.065
  3. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140.
    View in: PubMed
    Score: 0.064
  4. Perioperative considerations for neoadjuvant immunotherapy in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2020 Nov; 160(5):1376-1382.
    View in: PubMed
    Score: 0.063
  5. Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. J Surg Oncol. 2020 Sep; 122(3):495-505.
    View in: PubMed
    Score: 0.062
  6. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg. 2020 02; 109(2):358-366.
    View in: PubMed
    Score: 0.060
  7. Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. Ann Thorac Surg. 2020 02; 109(2):404-411.
    View in: PubMed
    Score: 0.060
  8. Centrally located lung cancer and risk of?occult nodal disease: an objective evaluation of multiple definitions of tumour centrality with dedicated imaging software. Eur Respir J. 2019 05; 53(5).
    View in: PubMed
    Score: 0.058
  9. Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm. Ann Thorac Surg. 2019 01; 107(1):277-284.
    View in: PubMed
    Score: 0.056
  10. Reply to "Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues". J Thorac Oncol. 2017 09; 12(9):e150-e151.
    View in: PubMed
    Score: 0.052
  11. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. Semin Thorac Cardiovasc Surg. 2017 Autumn; 29(3):408-415.
    View in: PubMed
    Score: 0.051
  12. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1.
    View in: PubMed
    Score: 0.046
  13. Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer. Ann Thorac Surg. 2016 Jan; 101(1):211-7.
    View in: PubMed
    Score: 0.045
  14. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013 Sep; 258(3):500-7.
    View in: PubMed
    Score: 0.039
  15. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg. 2010 Apr; 210(4):418-27.
    View in: PubMed
    Score: 0.031
  16. Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer. J Gastrointest Surg. 2009 Dec; 13(12):2121-7.
    View in: PubMed
    Score: 0.030
  17. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1444-1453.e4.
    View in: PubMed
    Score: 0.020
  18. The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 09; 166(3):637-654.
    View in: PubMed
    Score: 0.019
  19. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2024 Feb; 117(2):320-326.
    View in: PubMed
    Score: 0.019
  20. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be Delayed. Ann Surg. 2023 05 01; 277(5):721-726.
    View in: PubMed
    Score: 0.018
  21. Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 02 20; 40(6):546-555.
    View in: PubMed
    Score: 0.018
  22. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg. 2021 10 23; 108(10):1207-1215.
    View in: PubMed
    Score: 0.017
  23. Clinical Significance of [18F] Fluoro-2-Deoxy-d-Glucose/Computed Tomographic Avid Hilar Lymph Nodes in Esophageal Carcinoma Patients. Ann Thorac Surg. 2022 10; 114(4):1183-1188.
    View in: PubMed
    Score: 0.017
  24. Preoperative Maximum Standardized Uptake Value Associated With Recurrence Risk in Early Lung Cancer. Ann Thorac Surg. 2022 06; 113(6):1835-1844.
    View in: PubMed
    Score: 0.017
  25. Simultaneous versus staged resections for bilateral pulmonary metastases. J Surg Oncol. 2021 Jun; 123(7):1633-1639.
    View in: PubMed
    Score: 0.017
  26. Predictors of survival following surgical resection of limited-stage small cell lung cancer. J Thorac Cardiovasc Surg. 2021 Mar; 161(3):760-771.e2.
    View in: PubMed
    Score: 0.016
  27. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer. 2021 05; 22(3):e415-e424.
    View in: PubMed
    Score: 0.016
  28. Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. J Surg Oncol. 2020 Sep; 122(3):515-522.
    View in: PubMed
    Score: 0.016
  29. Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. J Thorac Cardiovasc Surg. 2021 Apr; 161(4):1497-1504.e2.
    View in: PubMed
    Score: 0.015
  30. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
    View in: PubMed
    Score: 0.015
  31. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3).
    View in: PubMed
    Score: 0.015
  32. Typical and atypical carcinoid tumors of the lung: a clinicopathological correlation of 783 cases with emphasis on histological features. Hum Pathol. 2020 04; 98:98-109.
    View in: PubMed
    Score: 0.015
  33. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer? Dis Esophagus. 2019 Dec 13; 32(10):1-6.
    View in: PubMed
    Score: 0.015
  34. Persistent opioid use is associated with worse survival after lobectomy for stage I non-small cell lung cancer. Pain. 2019 10; 160(10):2365-2373.
    View in: PubMed
    Score: 0.015
  35. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
    View in: PubMed
    Score: 0.015
  36. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Ann Thorac Surg. 2019 09; 108(3):845-851.
    View in: PubMed
    Score: 0.015
  37. Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience. Ann Thorac Surg. 2019 08; 108(2):370-376.
    View in: PubMed
    Score: 0.015
  38. Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. Ann Thorac Surg. 2018 11; 106(5):1499-1503.
    View in: PubMed
    Score: 0.014
  39. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2018 07; 156(1):406-413.e3.
    View in: PubMed
    Score: 0.013
  40. Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components. Ann Thorac Surg. 2018 07; 106(1):235-241.
    View in: PubMed
    Score: 0.013
  41. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424.
    View in: PubMed
    Score: 0.013
  42. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer. 2018 03 01; 124(5):1061-1069.
    View in: PubMed
    Score: 0.013
  43. Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1090-1097.
    View in: PubMed
    Score: 0.013
  44. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.013
  45. Thymoma: a clinicopathological correlation of 1470 cases. Hum Pathol. 2018 03; 73:7-15.
    View in: PubMed
    Score: 0.013
  46. Radiation Therapy is Independently Associated with Worse Survival After R0-Resection for Stage I-II Non-small Cell Lung Cancer: An Analysis of the National Cancer Data Base. Ann Surg Oncol. 2017 May; 24(5):1419-1427.
    View in: PubMed
    Score: 0.012
  47. Surgical resection for locoregional esophageal cancer is underutilized in the United States. J Am Coll Surg. 2010 Dec; 211(6):754-61.
    View in: PubMed
    Score: 0.008
  48. A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg. 2010 Oct; 252(4):611-7.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.